Beschreibung:
<jats:title>Abstract</jats:title><jats:sec><jats:title>Background</jats:title><jats:p>The novel blood based biomarkers have shown such promising results, and these developments coincide with the approval of the first AD drugs. This needs to consider clinical implementation. Are we there yet? What steps need to be undertaken to make that happen? Can we implement these biomarkers, as single markers or as combinations in secondary care, primary care, or in‐between to avoid health care system overload?</jats:p></jats:sec><jats:sec><jats:title>Method</jats:title><jats:p>This presentation will give an overview of steps be taken and currently ongoing.</jats:p></jats:sec><jats:sec><jats:title>Result</jats:title><jats:p>I will address clinical studies in different settings, technical developments on the level of assays and standardization of lab‐protocols and regulatory approval. In addition, i will discuss possible context of use and definition of appropriate use recommendations by the Alzheimer Association working group.</jats:p></jats:sec><jats:sec><jats:title>Conclusion</jats:title><jats:p>The exact context and appropriate use of BBB are to be defined in the next few years.</jats:p></jats:sec>